A well-known inhibitory Notch ligand is delta-like ligand 3 (DLL3), which is highly expressed in SCLC and minimally expressed in normal tissue, and is emerging as a promising molecular target for novel targeted drugs [95,96]. This evidence concerns the gene DLL3 and small cell lung carcinoma.